Clinical benefit within patient subgroups receiving c7E3 Fab (abciximab) during percutaneous coronary revascularization: Subgroup analysis from the EPIC trial

Frank V. Aguirre, Eric J. Topol, Keaven M. Anderson, Neal S. Kleiman, Harlan F. Weisman, Susan E. FitzPatrick, Robert M. Califf

Research output: Contribution to journalArticle

5 Scopus citations
Original languageEnglish (US)
Pages (from-to)21B-29B
JournalJournal of Invasive Cardiology
Volume8
Issue numberSUPPL. B
StatePublished - 1996
Externally publishedYes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this